Supplement: Margaret Foti

Margaret Foti By Anne Harding Devoting her life to cancer research DUSTIN FENSTERMACHER / WONDERFUL MACHINE RELATED ARTICLES Successful Strategies The Launch and the Exit Entrepreneurs Boldly Break New Ground Mark Tykocinski: Open doors lead a scientist to his calling Shire Pharmaceuticals: A Study in Exponential Growth Many Happy Returns: Cephalon celebrates its 20th year Creative Collaboration When Margaret Foti became the first chief

Written byAnne Harding
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Successful Strategies

The Launch and the Exit

Entrepreneurs Boldly Break New Ground

Mark Tykocinski: Open doors lead a scientist to his calling

Shire Pharmaceuticals: A Study in Exponential Growth

Many Happy Returns: Cephalon celebrates its 20th year

Creative Collaboration

When Margaret Foti became the first chief executive officer of the American Association for Cancer Research (AACR) in 1982, the organization had a $1 million budget, published one journal, had 4,000 members, and sponsored a single annual meeting.

Today, the AACR boasts a budget of $44 million, publishes six journals, has more than 27,000 members, and holds 25 scientific events every year. The association will soon launch a new journal, on cancer prevention, and plans to add more than 200 to its staff of 140 over the next several years.

"I'm very proud to say we are the most prestigious cancer research organization in the world," says Foti. "Everyone looks ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies